Obermatt
See Similar Stocks →

Nurix Therapeutics

NMQ:NRIX · US67080M1036
BiotechnologySmall

360

18
Profit price37
Cash yield1
Price/Sales63
Price/Book14
Return on Capital20
Cash Return on Capital29
Return on Equity29
Profit margins4
Accruals50
Owner Earnings Margin29
Sales growth26
Profit growth13
Reinvestment8
Price momentum29
Debt load38
Refinancing27
Debt Payback1
Liquidity55
Analyst ratings53
Opinion Changes50
Price Target Upside48
Market mood75
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Nurix Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded2009
Employees328
Websitenurixtx.com
ISINUS67080M1036
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
RheumatologyInflammationOncologyChronic DiseasesImmunologyBiotechnologyHealth CareMedical

Description

Nurix Therapeutics, Inc. and its wholly owned subsidiaries (Nurix) operate as a clinical stage biopharmaceutical company. Nurix Therapeutics focuses on the discovery, development, and commercialization of targeted protein degradation medicines, whic…

Analysis

Middle-of-the-road

Nurix Therapeutics, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 0/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
28
2026

All-time high

28

Jun 2026

All-time low

13

Mar 2026

Average rank

21

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
63
—
—
—
Price/Earnings
48
—
—
—
Price/Book
14
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
59
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Nurix Therapeutics with its peers
Zymeworks
NSQ:ZYME
43
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Kymera Therapeutics
NMQ:KYMR
30
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Aclaris Therapeutics
NSQ:ACRS
28
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Prelude Therapeutics
NSQ:PRLD
49
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Schrödinger
NSQ:SDGR
14
CountryUSA
IndustryHealth Care Technology
SizeMedium
Full Stock Analysis →
Disc Medicine
NMQ:IRON
5
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →